CONNECT expands with new partner

Kristie van Lieshout, Market Access & Healthcare Affairs Manager, Boehringer Ingelheim Norway ”Being part of the CONNECT Consortium will allow us to effectively advocate and be involved in projects, clinical trials, and share experience and knowledge with pharmaceutical companies, healthcare professionals and the public sector.”

Who we are

Family-owned since its foundation in 1885, Boehringer Ingelheim is one of the world’s leading research-based pharmaceutical companies, serving over 130 markets. Boehringer Ingelheim develops therapeutic breakthroughs that transform lives – today and for generations to come. It is divided into two business areas: Human Pharma and Animal Health. Human Pharma research focuses on therapeutic areas of cardiovascular and metabolic health, cancer, mental health, eye health and inflammatory diseases.

Already today, we are helping millions of people worldwide live longer, healthier lives. But our ultimate goal is to create social impact for the entire population – capable of serving every patient. To achieve this, we address health equity and wellbeing across the whole patient continuum of care: from pharmaceutical innovation over prevention and healthcare delivery to tackling equitable access. We focus on rapid innovation, integrating sustainability along our value chain and fostering multi-stakeholder collaboration.

Why precision medicine is important for Boehringer Ingelheim & why this collaboration

We are a company that aim to drive scientific innovation for more people living with cancer; this includes understanding patient community needs, priorities and the healthcare systems they navigate in.

We want to pave the way for meaningful change by building solutions in collaboration with the healthcare community to problems that impact cancer patients across Norway including access to precision cancer medicine.

Precision cancer medicine is a novel approach for patients with cancer and throughout this partnership, we want to share knowledge and to effectively advocate for improved care, access, and support for those impacted by cancer in Norway.

Precision medicine can be complex to initiate, and it can take a long time for patients to get access – this is why a close collaboration between pharmaceutical industry, the healthcare professional community and regulatory entities is important and being part of the CONNECT Consortium is in line with Boehringer Ingelheim’s commitment to patients.